Oxcia appoints Dr. Sandra Ekstedt as new Preclinical Director
She brings over a decade of respiratory disease expertise and will lead preclinical development of OXC-201.
See the latest news and media coverage for Oxcia. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company targeting DNA damage repair and oxidative stress
oxcia.comLast updated
In short: Oxcia advanced its clinical pipeline, secured a new Canadian patent for OXC-201, and strengthened its leadership and advisory boards.
She brings over a decade of respiratory disease expertise and will lead preclinical development of OXC-201.
The annual report is available on the website and the CEO comments on the first collaboration agreement as well as ODD from two supervisory authorities.
The meeting will consider authorization for issuance of shares, warrants, and convertibles.
Patent already approved in US, Japan, China; pending in Europe, valid until March 2039
Article ‘Count’ and ‘Share’ for Oxcia AB based on listed parameters only. According to the parameters selected above, there are no articles from Oxcia AB...
Track Oxcia and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Oxcia and other trending companies.